What is the address of Dr. Steven Reremoser - Heelkunde?

The registered office of Dr. Steven Reremoser - Heelkunde is located at Koninklijkelaan 20, 2600 Antwerpen.

Is Dr. Steven Reremoser - Heelkunde still active?

Yes. According to the CBE (3 October 2026) Dr. Steven Reremoser - Heelkunde is active, legal situation “Normale toestand”, started on 9 November 2012.

Is Dr. Steven Reremoser - Heelkunde registered on Peppol?

Yes, Dr. Steven Reremoser - Heelkunde is registered on the Peppol network with ID 0208:0500706377.

What is the enterprise number of Dr. Steven Reremoser - Heelkunde?

The enterprise number of Dr. Steven Reremoser - Heelkunde is BE0500706377.

When was Dr. Steven Reremoser - Heelkunde founded?

Dr. Steven Reremoser - Heelkunde was founded on 9 November 2012.

Who are the directors of Dr. Steven Reremoser - Heelkunde?

According to the 2025 annual accounts, the directors of Dr. Steven Reremoser - Heelkunde are: STEVEN REREMOSER.

Is Dr. Steven Reremoser - Heelkunde a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 November 2012; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Steven Reremoser - Heelkunde make in 2025?

Dr. Steven Reremoser - Heelkunde posted a profit after taxes of € 257,073 in financial year 2025.

What is the revenue of Dr. Steven Reremoser - Heelkunde?

As a small company, Dr. Steven Reremoser - Heelkunde is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 347,842.

Dr. Steven Reremoser - Heelkunde (Private Limited)

Dossier Dr. Steven Reremoser - Heelkunde, printed on 3 October 2026 from databakkes.be/en/0500706377/dr-steven-reremoser-heelkunde. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Steven Reremoser - Heelkunde from Antwerpen, company number BE0500706377, closed financial year 2025 with a result of € 257,073 after tax. For that financial year Dr. Steven Reremoser - Heelkunde recorded a gross margin of € 347,842 and equity of € 628,349. Compared with financial year 2024, the result moved from € 225,155 to € 257,073. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.

What it is worth Growing

€ 628,349

▲ 10% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 257,073

▲ 14% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 170,200

▼ 18% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 200,736 paid out

78 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt

€ 34,285

▲ € 34,182 vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 459

▼ 97% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 52,084

▲ 41% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 198,865 Gross margin 2022: € 198,865 First fiscal year in the series	€ 274,978 Gross margin 2023: € 274,978 ▲ 38% vs 2022 (€ 198,865) Favourable step	€ 293,568 Gross margin 2024: € 293,568 ▲ 7% vs 2023 (€ 274,978) Favourable step	€ 347,842 Gross margin 2025: € 347,842 ▲ 18% vs 2024 (€ 293,568) Favourable step	▲ 18%
Profit after taxes	€ 141,864 Profit after taxes 2022: € 141,864 First fiscal year in the series	€ 203,124 Profit after taxes 2023: € 203,124 ▲ 43% vs 2022 (€ 141,864) Favourable step	€ 225,155 Profit after taxes 2024: € 225,155 ▲ 11% vs 2023 (€ 203,124) Favourable step	€ 257,073 Profit after taxes 2025: € 257,073 ▲ 14% vs 2024 (€ 225,155) Favourable step	▲ 14%
Equity	€ 361,713 Equity 2022: € 361,713 First fiscal year in the series	€ 489,004 Equity 2023: € 489,004 ▲ 35% vs 2022 (€ 361,713) Favourable step	€ 572,013 Equity 2024: € 572,013 ▲ 17% vs 2023 (€ 489,004) Favourable step	€ 628,349 Equity 2025: € 628,349 ▲ 10% vs 2024 (€ 572,013) Favourable step	▲ 10%
Total debts	€ 24,911 Total debts 2022: € 24,911 First fiscal year in the series	€ 32,829 Total debts 2023: € 32,829 ▲ 32% vs 2022 (€ 24,911) Unfavourable step	€ 53,527 Total debts 2024: € 53,527 ▲ 63% vs 2023 (€ 32,829) Unfavourable step	€ 86,928 Total debts 2025: € 86,928 ▲ 62% vs 2024 (€ 53,527) Unfavourable step	▲ 62%
Cash	€ 38,102 Cash 2022: € 38,102 First fiscal year in the series	€ 130,410 Cash 2023: € 130,410 ▲ 242% vs 2022 (€ 38,102) Favourable step	€ 207,952 Cash 2024: € 207,952 ▲ 59% vs 2023 (€ 130,410) Favourable step	€ 170,200 Cash 2025: € 170,200 ▼ 18% vs 2024 (€ 207,952) Unfavourable step	▼ 18%
Land & buildings	€ 36,125 Land & buildings 2022: € 36,125 First fiscal year in the series	€ 32,766 Land & buildings 2023: € 32,766 ▼ 9% vs 2022 (€ 36,125) Unchanged	€ 29,407 Land & buildings 2024: € 29,407 ▼ 10% vs 2023 (€ 32,766) Unchanged	€ 26,550 Land & buildings 2025: € 26,550 ▼ 10% vs 2024 (€ 29,407) Unchanged	▼ 10%
Retained profit	€ 343,113 Retained profit 2022: € 343,113 First fiscal year in the series	€ 470,404 Retained profit 2023: € 470,404 ▲ 37% vs 2022 (€ 343,113) Favourable step	€ 553,413 Retained profit 2024: € 553,413 ▲ 18% vs 2023 (€ 470,404) Favourable step	€ 609,749 Retained profit 2025: € 609,749 ▲ 10% vs 2024 (€ 553,413) Favourable step	▲ 10%
Dividend	€ 61,819 Dividend 2022: € 61,819 First fiscal year in the series	€ 75,833 Dividend 2023: € 75,833 ▲ 23% vs 2022 (€ 61,819) Unchanged	€ 142,146 Dividend 2024: € 142,146 ▲ 87% vs 2023 (€ 75,833) Unchanged	€ 200,736 Dividend 2025: € 200,736 ▲ 41% vs 2024 (€ 142,146) Unchanged	▲ 41%
Bank debt	€ 15,000 Bank debt 2022: € 15,000 First fiscal year in the series	€ 490 Bank debt 2023: € 490 ▼ 97% vs 2022 (€ 15,000) Favourable step	€ 104 Bank debt 2024: € 104 ▼ 79% vs 2023 (€ 490) Favourable step	€ 34,285 Bank debt 2025: € 34,285 ▲ € 34,182 vs 2024 (€ 104) Unfavourable step	▲ € 34,182
Balance sheet total	€ 386,625 Balance sheet total 2022: € 386,625 First fiscal year in the series	€ 521,834 Balance sheet total 2023: € 521,834 ▲ 35% vs 2022 (€ 386,625) Unchanged	€ 625,539 Balance sheet total 2024: € 625,539 ▲ 20% vs 2023 (€ 521,834) Unchanged	€ 715,277 Balance sheet total 2025: € 715,277 ▲ 14% vs 2024 (€ 625,539) Unchanged	▲ 14%

Key figures of Dr. Steven Reremoser - Heelkunde, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Steven Reremoser - Heelkunde?

What happened at Dr. Steven Reremoser - Heelkunde in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 29, 2026 New annual accounts for financial year 2025: profit of € 257,073 (▲ 14% vs 2024). filed late Source: NBB ↗
Nov 9, 2012 New establishment in Antwerpen. KBO
Nov 9, 2012 Start of the company according to the CBE. KBO

In short

From € 141,864 profit in 2022 to € 257,073 profit in 2025.

Paid € 265,267 in corporate taxes since 2022.

Best year ever: 2025, with € 257,073 profit.

Paid out € 480,534 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Steven Reremoser - Heelkunde? We notify you, reason included.

Follow Dr. Steven Reremoser - Heelkunde

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

STEVEN REREMOSER

Dr. Steven Reremoser - Heelkunde

Behind Dr. Steven Reremoser - Heelkunde is STEVEN REREMOSER.

See the full network in the app

Directors

According to the 2025 annual accounts

STEVEN REREMOSER

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Koninklijkelaan 20

2600 Antwerpen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Dr. Isabelle Meire, Gynaecologie

€ 118,605 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0500.706.377
VAT number: BE 0500.706.377
Registered office: Koninklijkelaan 20, 2600 Antwerpen
Names & denominations: Dr. Steven Reremoser - Heelkunde
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 9 November 2012
Peppol: Active · Active since 5 Jan 2026

View on CBE Public ↗ Annual accounts (NBB) ↗